-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] As of now, a large number of pharmaceutical companies' 2021 financial reports have been released
.
Among them, it is worth noting that according to the annual reports of many multinational pharmaceutical companies, the Chinese market still provides important opportunities for many pharmaceutical companies and contributed a lot of performance
.
Sanofi Sanofi's 2021 net income is 37.
761 billion euros ($43.
0 billion), a year-on-year increase of 7.
1% - of which the pharmaceutical business revenue will total 26.
970 billion euros (+7.
6%) and the vaccine business income will be 6.
323 billion euros (+6.
8%) , Consumer health business revenue 4.
468 billion euros (+4.
6%)
.
Among them, China's revenue in 2021 was 2.
720 billion euros (3.
098 billion U.
S.
dollars), a year-on-year increase of 7.
9%, mainly due to the growth of Dupixent and the recovery of Plavix (clopidogrel) from the impact of bulk purchases
.
On April 28, Sanofi announced its 2022Q1 results, achieving revenue of 9.
674 billion euros, a year-on-year increase of 8.
6%
.
In the Chinese market, Sanofi's revenue continued to improve, with a year-on-year increase of 13.
4% (901 million euros)
.
Its announcement stated that it is mainly benefiting from the growth of Dupixent (duplimumab) and the promotion of vaccines
.
However, the procurement of insulin with volume is expected to be implemented in May 2022, and Sanofi expects that the sales of the two winning products, Toujeo/Lantus China, will drop by about 30% in 2022
.
Novartis Novartis announced its financial report that the company's 2021 fiscal year annual report attributable to the parent company's common shareholders' net profit increased by 197.
58% year-on-year to $24.
021 billion; operating income increased by 5.
97% year-on-year to $52.
877 billion
.
Novartis' sales revenue in the Chinese market in 2021 will increase by 18% year-on-year to US$3.
052 billion, accounting for 6% of Novartis' total global revenue
.
Novartis stated in the financial report that the increase in medical insurance has become the main driving force
.
It is reported that Novartis’ leading product, secukinumab, will be included in the national medical insurance list in 2020, and the demand will be quickly released
.
It is worth mentioning that Novartis recently announced its first quarter results for 2022
.
Group net sales were US$12.
5 billion, up 5% year-on-year; operating profit was US$2.
852 billion, up 26% year-on-year; net sales in China were US$880 million, up 16% year-on-year
.
Novo Nordisk Novo Nordisk's 2021 fiscal year annual report net profit attributable to ordinary shareholders of the parent company increased by 13.
33% year-on-year to 47.
757 billion Danish kroner (about 7.
593 billion US dollars); operating income increased by 10.
91% year-on-year to 140.
800 billion Danish kroner (approximately $22.
385 billion)
.
In China, Novo Nordisk's performance was DKK 16.
019 billion (about 2.
547 billion US dollars), a year-on-year increase of 14%
.
It is reported that with the blessing of medical insurance, the sales of Novo Nordisk's blockbuster hypoglycemic drug liraglutide in China will be 1.
544 billion Danish kroner (about 245 million US dollars, about 1.
6 billion yuan) in 2021.
species increased by as much as 45% year-on-year
.
Another new diabetes drug, semaglutide, was sold for 303 million Danish kroner (about 48 million US dollars, about 300 million yuan) in just over half a year after it was launched, and passed the national medical insurance negotiation last year
.
AstraZeneca will achieve revenue of US$6.
011 billion in 2021, a year-on-year increase of 12%.
China is one of the important sources of AstraZeneca's revenue
.
However, due to the pressure of price reduction caused by medical insurance negotiations and centralized procurement, AstraZeneca's annual revenue in China dropped from US$1.
362 billion in the same period of fiscal 2020 to US$1.
312 billion, and its share of global revenue fell from 20% in 2020 to 16%
.
The industry expects that due to the continuous impact of centralized procurement and medical insurance, AstraZeneca's performance in China may also experience a mid-single-digit decline in 2022
.
According to the 2021 annual report released by Merck, the company's revenue in 2021 will increase by 17% year-on-year to $48.
704 billion
.
Among them, Merck China's total revenue increased by 60% year-on-year to US$4.
262 billion, accounting for 8.
75% of the global total
.
The announcement shows that the explosive growth of its performance is mainly due to Keytruda (PD-1, pembrolizumab, pembrolizumab) and 4/9-valent HPV vaccine, lenvatinib, olaparib and other products
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, it is worth noting that according to the annual reports of many multinational pharmaceutical companies, the Chinese market still provides important opportunities for many pharmaceutical companies and contributed a lot of performance
.
Sanofi Sanofi's 2021 net income is 37.
761 billion euros ($43.
0 billion), a year-on-year increase of 7.
1% - of which the pharmaceutical business revenue will total 26.
970 billion euros (+7.
6%) and the vaccine business income will be 6.
323 billion euros (+6.
8%) , Consumer health business revenue 4.
468 billion euros (+4.
6%)
.
Among them, China's revenue in 2021 was 2.
720 billion euros (3.
098 billion U.
S.
dollars), a year-on-year increase of 7.
9%, mainly due to the growth of Dupixent and the recovery of Plavix (clopidogrel) from the impact of bulk purchases
.
On April 28, Sanofi announced its 2022Q1 results, achieving revenue of 9.
674 billion euros, a year-on-year increase of 8.
6%
.
In the Chinese market, Sanofi's revenue continued to improve, with a year-on-year increase of 13.
4% (901 million euros)
.
Its announcement stated that it is mainly benefiting from the growth of Dupixent (duplimumab) and the promotion of vaccines
.
However, the procurement of insulin with volume is expected to be implemented in May 2022, and Sanofi expects that the sales of the two winning products, Toujeo/Lantus China, will drop by about 30% in 2022
.
Novartis Novartis announced its financial report that the company's 2021 fiscal year annual report attributable to the parent company's common shareholders' net profit increased by 197.
58% year-on-year to $24.
021 billion; operating income increased by 5.
97% year-on-year to $52.
877 billion
.
Novartis' sales revenue in the Chinese market in 2021 will increase by 18% year-on-year to US$3.
052 billion, accounting for 6% of Novartis' total global revenue
.
Novartis stated in the financial report that the increase in medical insurance has become the main driving force
.
It is reported that Novartis’ leading product, secukinumab, will be included in the national medical insurance list in 2020, and the demand will be quickly released
.
It is worth mentioning that Novartis recently announced its first quarter results for 2022
.
Group net sales were US$12.
5 billion, up 5% year-on-year; operating profit was US$2.
852 billion, up 26% year-on-year; net sales in China were US$880 million, up 16% year-on-year
.
Novo Nordisk Novo Nordisk's 2021 fiscal year annual report net profit attributable to ordinary shareholders of the parent company increased by 13.
33% year-on-year to 47.
757 billion Danish kroner (about 7.
593 billion US dollars); operating income increased by 10.
91% year-on-year to 140.
800 billion Danish kroner (approximately $22.
385 billion)
.
In China, Novo Nordisk's performance was DKK 16.
019 billion (about 2.
547 billion US dollars), a year-on-year increase of 14%
.
It is reported that with the blessing of medical insurance, the sales of Novo Nordisk's blockbuster hypoglycemic drug liraglutide in China will be 1.
544 billion Danish kroner (about 245 million US dollars, about 1.
6 billion yuan) in 2021.
species increased by as much as 45% year-on-year
.
Another new diabetes drug, semaglutide, was sold for 303 million Danish kroner (about 48 million US dollars, about 300 million yuan) in just over half a year after it was launched, and passed the national medical insurance negotiation last year
.
AstraZeneca will achieve revenue of US$6.
011 billion in 2021, a year-on-year increase of 12%.
China is one of the important sources of AstraZeneca's revenue
.
However, due to the pressure of price reduction caused by medical insurance negotiations and centralized procurement, AstraZeneca's annual revenue in China dropped from US$1.
362 billion in the same period of fiscal 2020 to US$1.
312 billion, and its share of global revenue fell from 20% in 2020 to 16%
.
The industry expects that due to the continuous impact of centralized procurement and medical insurance, AstraZeneca's performance in China may also experience a mid-single-digit decline in 2022
.
According to the 2021 annual report released by Merck, the company's revenue in 2021 will increase by 17% year-on-year to $48.
704 billion
.
Among them, Merck China's total revenue increased by 60% year-on-year to US$4.
262 billion, accounting for 8.
75% of the global total
.
The announcement shows that the explosive growth of its performance is mainly due to Keytruda (PD-1, pembrolizumab, pembrolizumab) and 4/9-valent HPV vaccine, lenvatinib, olaparib and other products
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
